Prostate cancer and markers of bone metabolism: Diagnostic, prognostic, and therapeutic implications

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Knowledge of bone metastases complicating advanced prostate cancer (CaP) is increasingly relevant in patient selection for novel therapies. Current nuclear bone scintigraphy imaging has limited specificity for prostate metastases. As serum bone markers do correlate with bony lesions, they may play multiple roles in patients with advanced CaP. Currently, these markers play a role in prognostic nomograms for CaP. Recent studies suggest an expanding role for bone markers in the diagnosis and selection of patients for novel therapies. In the future, therapeutic roles for some of these marker pathways will emerge, eventually allowing greater individualization of patient care.

Original languageEnglish (US)
Pages (from-to)393-399
Number of pages7
JournalWorld Journal of Urology
Volume25
Issue number4
DOIs
StatePublished - Aug 2007

Fingerprint

Bone Neoplasms
Prostatic Neoplasms
Bone and Bones
Patient Selection
Neoplasm Metastasis
Nomograms
Therapeutics
Radionuclide Imaging
Prostate
Patient Care
Biomarkers

Keywords

  • Androgen-independent prostate cancer
  • Bone markers
  • Bone metastases
  • Osteoprotegerin
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

@article{7b195e48ea2548d7a9905492e159e81e,
title = "Prostate cancer and markers of bone metabolism: Diagnostic, prognostic, and therapeutic implications",
abstract = "Knowledge of bone metastases complicating advanced prostate cancer (CaP) is increasingly relevant in patient selection for novel therapies. Current nuclear bone scintigraphy imaging has limited specificity for prostate metastases. As serum bone markers do correlate with bony lesions, they may play multiple roles in patients with advanced CaP. Currently, these markers play a role in prognostic nomograms for CaP. Recent studies suggest an expanding role for bone markers in the diagnosis and selection of patients for novel therapies. In the future, therapeutic roles for some of these marker pathways will emerge, eventually allowing greater individualization of patient care.",
keywords = "Androgen-independent prostate cancer, Bone markers, Bone metastases, Osteoprotegerin, Prostate cancer",
author = "Nelson, {Eric C.} and Evans, {Christopher P} and Chong-Xian Pan and Lara, {Primo N}",
year = "2007",
month = "8",
doi = "10.1007/s00345-007-0186-3",
language = "English (US)",
volume = "25",
pages = "393--399",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Prostate cancer and markers of bone metabolism

T2 - Diagnostic, prognostic, and therapeutic implications

AU - Nelson, Eric C.

AU - Evans, Christopher P

AU - Pan, Chong-Xian

AU - Lara, Primo N

PY - 2007/8

Y1 - 2007/8

N2 - Knowledge of bone metastases complicating advanced prostate cancer (CaP) is increasingly relevant in patient selection for novel therapies. Current nuclear bone scintigraphy imaging has limited specificity for prostate metastases. As serum bone markers do correlate with bony lesions, they may play multiple roles in patients with advanced CaP. Currently, these markers play a role in prognostic nomograms for CaP. Recent studies suggest an expanding role for bone markers in the diagnosis and selection of patients for novel therapies. In the future, therapeutic roles for some of these marker pathways will emerge, eventually allowing greater individualization of patient care.

AB - Knowledge of bone metastases complicating advanced prostate cancer (CaP) is increasingly relevant in patient selection for novel therapies. Current nuclear bone scintigraphy imaging has limited specificity for prostate metastases. As serum bone markers do correlate with bony lesions, they may play multiple roles in patients with advanced CaP. Currently, these markers play a role in prognostic nomograms for CaP. Recent studies suggest an expanding role for bone markers in the diagnosis and selection of patients for novel therapies. In the future, therapeutic roles for some of these marker pathways will emerge, eventually allowing greater individualization of patient care.

KW - Androgen-independent prostate cancer

KW - Bone markers

KW - Bone metastases

KW - Osteoprotegerin

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=34548175778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548175778&partnerID=8YFLogxK

U2 - 10.1007/s00345-007-0186-3

DO - 10.1007/s00345-007-0186-3

M3 - Article

C2 - 17562051

AN - SCOPUS:34548175778

VL - 25

SP - 393

EP - 399

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 4

ER -